Early development of sigma-receptor ligands

Area of Science:

• Neuroscience
• Pharmacology
• Oncology

Background:

• Sigma receptors (σ-1 and σ-2) are non-opioid proteins involved in neurological disorders and cancer.
• The σ-1 subtype acts as a chaperon protein in the central nervous system (CNS) and peripheral tissues, modulating signaling cascades and neurotransmitter release.
• σ-2 receptors are lipid raft proteins highly expressed on tumor cells, making them potential anticancer drug targets.

Purpose of the Study:

• To review the early development of sigma receptor-specific ligands.
• To discuss the development of radiolabeling agents for sigma receptors.
• To highlight the therapeutic potential of sigma receptors in neuropsychiatric diseases and cancer.

Main Methods:

• Literature review of early research on sigma receptor ligands.
• Analysis of studies on the development of radiolabeled sigma receptor agents.
• Synthesis of information on the role of sigma receptors in disease pathophysiology.

Main Results:

• Sigma-1 receptors are emerging targets for treating neuropsychiatric conditions like schizophrenia, depression, and cocaine addiction.
• Sigma-2 receptors' high expression on tumor cells presents opportunities for anticancer drug development.
• A diverse range of compounds, including neurosteroids and synthetic drugs, bind to sigma receptors.

Conclusions:

• Sigma receptors represent promising therapeutic targets for both neurological disorders and cancer.
• Further development of sigma receptor-specific ligands and radiolabeling agents is crucial for advancing treatment strategies.
• Understanding sigma receptor pharmacology is essential for drug discovery in these areas.